Exploration of Gait Biomechanics and Muscle Pain of the Lower Extremity

NCT ID: NCT06411197

Last Updated: 2025-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-08

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This interventional study aims to test gait biomechanics in healthy individuals with and without experimental muscle pain in the lower extremities. The study aims to:

A) Examine how experimental muscle pain in different types of muscles (ankle plantar-flexion, knee extension, and flexion muscles) affects kinematics, kinetics, and muscle activation

Participants will receive six muscle injections: a) Hypertonic saline (painful condition) and b) Isotonic saline (control condition) in 1) m. gastrocnemius, 2) m. semitendinosus, and 3) m. biceps femoris.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study will be a randomized, crossover design in which experimental pain will be induced in healthy subjects using hypertonic saline injections to three muscles of the lower extremities: The gastrocnemius muscle, the vastus medialis muscle, and the semitendinosus muscle. Participants will be block-randomized to receive an injection in each of the three muscles and will receive either the painful or control condition first for each muscle. The participant will always be blinded to the type of injection received.

Following the injection, there will typically be a 15-minute window of pain (45). Within this timeframe, motion capture will be carried out for both the control and painful conditions. During motion capture, the participants will perform multiple walking trials of approximately 10 meters. The participants will be equipped with electromyography (EMG) sensors on key muscles of the lower extremities. The participants will be asked for NRS ratings every 30 seconds throughout the 15 minutes with expected pain. There will be a 15-minute washout between the muscle injections.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gastrocnemius (painful condition)

1.5 mL injection of hypertonic saline (7%) to the gastrocnemius muscle.

Group Type EXPERIMENTAL

Hypertonic saline injection

Intervention Type OTHER

Injection with hypertonic saline (7%)

Gastrocnemius (control condition)

1.5 mL injection of isotonic saline (0.9%) to the gastrocnemius muscle.

Group Type SHAM_COMPARATOR

Isotonic saline injection

Intervention Type OTHER

Injection with isotonic saline (0.9%)

Biceps femoris (painful condition)

1.2 mL injection of hypertonic saline (7%) to the biceps femoris muscle.

Group Type EXPERIMENTAL

Hypertonic saline injection

Intervention Type OTHER

Injection with hypertonic saline (7%)

Biceps femoris (control condition)

1.2 mL injection of isotonic saline (0.9%) to the biceps femoris muscle.

Group Type SHAM_COMPARATOR

Isotonic saline injection

Intervention Type OTHER

Injection with isotonic saline (0.9%)

Semitendinosus (painful condition)

1.2 mL injection of hypertonic saline (7%) to the semitendinosus muscle.

Group Type EXPERIMENTAL

Hypertonic saline injection

Intervention Type OTHER

Injection with hypertonic saline (7%)

Semitendinosus (control condition)

1.2 mL injection of isotonic saline (7%) to the semitendinosus muscle.

Group Type SHAM_COMPARATOR

Isotonic saline injection

Intervention Type OTHER

Injection with isotonic saline (0.9%)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypertonic saline injection

Injection with hypertonic saline (7%)

Intervention Type OTHER

Isotonic saline injection

Injection with isotonic saline (0.9%)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy men and women aged 18-45 years

Exclusion Criteria

* Pregnancy
* Drug addiction, defined as the use of cannabis, opioids, or other drugs
* Previous or current neurologic or musculoskeletal illnesses
* Current pain
* Lack of ability to cooperate
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kristian Kjær Petersen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kristian Kjær Petersen

Associate professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kristian KS Petersen

Role: PRINCIPAL_INVESTIGATOR

Aalborg University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aalborg University

Aalborg, North Denmark, Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kristian KS Petersen

Role: CONTACT

Emma Hertel

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kristian KS Petersen

Role: primary

Emma Hertel

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N-20220063-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.